Physician profile
Devyn Dempsey
NPI 1821679978
$1,282.80
in general payments reported to CMS, 2019-2025
14 companies · $19.86 in 2025
The $19.86 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.53 · 2022: $345 · 2023: $393 · 2024: $473 · 2025: $19.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $199.21 | 2022 | |
| Axonics, INC. | $154.31 | 2023-2024 | Bulkamid, Axonics |
| Sumitomo Pharma America, INC. | $140.21 | 2023 | Myfembree |
| Gynesonics, INC. | $138.71 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Eisai INC. | $113.06 | 2023 | |
| Heron Therapeutics, INC. | $100.80 | 2024 | Zynrelef |
| Astellas Pharma US INC | $97.96 | 2023 | Veozah |
| Minerva Surgical, INC | $65.88 | 2022 | |
| Medicem INC. | $62.68 | 2022 | |
| Organon LLC | $57.97 | 2023-2024 | Jada System |
| Baxter Healthcare | $51.53 | 2021 | |
| Mimedx Group, INC. | $48.00 | 2024 | |
| Coopersurgical, INC. | $32.62 | 2022-2023 | Paragard T 380a |
| Otsuka America Pharmaceutical, INC. | $19.86 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.